TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00991731

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Faith-based
Description: The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-faith-based
Description: The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
Study: NCT04546100

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maternal-Infant Exercise Program
Description: Maternal-Infant Exercise Program can be divided into three videos stages. As time progresses during the three months, the parent-child exercise videos provided will have stronger intensity. The content includes general post-natal exercises (e.g., baby Lying on the mother's bed, raising legs or back of hands exercises, breast exercises; neck exercises; pelvic swinging exercises), aerobic exercises (e.g. walking with strollers, walking with baby on back), core exercises (e.g. kneeling balance, kneeling Push ups, stick exercises, modified side stick exercises) and hip and leg exercises (such as donkey kicks, side lifts), etc., with relaxing music during exercise.
Study: NCT01901536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Foundations Coparenting Program
Description: Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff.
Study: NCT02135042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study: NCT00188214

Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced dynamic CT perfusion study
Description: contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
Study: NCT00740181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study: NCT01378117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 50-100mg po once daily
Study: NCT01378117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine
Description: glargine once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lispro
Description: lispro before meals
Study: NCT03767049

Intervention type: OTHER
Intervention: Colection of clinical data
Description: Colection of clinical data
Study: NCT01656161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin embonate 22.5 mg
Study: NCT03053128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac shock wave therapy
Description: Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
Study: NCT03053128

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham cardiac shock wave (Control group)
Description: Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
Study: NCT00226005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTK787/ZK222584
Description: One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
Study: NCT01527630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
Study: NCT02315547

Intervention type: DRUG
Group type: OTHER
Intervention: Antibiotics
Description: Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline \[16\]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
Study: NCT04208269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postcard campaign
Description: Post card sent to parent only
Study: NCT01074125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
Study: NCT04052009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional gait training
Description: Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: End-effector based gait training
Description: Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: combined training (conventional and end-effector-based)
Description: Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
Study: NCT02951780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3185643
Description: Administered SC
Study: NCT02951780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rGlucagon
Description: Administered SC
Study: NCT00492453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
Study: NCT01402921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V0322 BC
Description: * Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: V0322 BC
Description: * Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~* The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~* 3 months duration daily treatment
Study: NCT02359903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab (BCD-055)
Description: infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab (Remicade)
Study: NCT01855386

Intervention type: OTHER
Intervention: Subjects with Gestational Diabetes
Description: Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.

Intervention type: OTHER
Intervention: Controls without Gestational Diabetes
Description: Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
Study: NCT03306550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salvianolate injection
Description: The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salvianolate injection
Description: The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Tablet
Description: Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Tablet
Description: Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
Study: NCT01769924

Intervention type: OTHER
Intervention: Nephrectomy
Description: Nephrectomy for the purposes of living kidney donation
Study: NCT02639689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WALKAIDE
Description: A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device.
Study: NCT01663792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seaweed
Description: Ten 500-mg capsules to be taken orally each day for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ten 500-mg capsules to be taken orally each day for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo2
Description: Ten 500-mg capsules to be taken orally each day for 1 month
Study: NCT03508050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clamping the Double Lumen Tube
Description: Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
Study: NCT01465009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
Study: NCT01246882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented activity feedback
Description: Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
Study: NCT02135042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo clinical observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study: NCT04208269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Information Technology system
Description: Accessed by adolescent and provider only

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Information Technology system
Description: Accessed by adolescent and provider only
Study: NCT02335515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soctec
Description: Gastroretentive Drug Delivery System
Study: NCT02477852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: preoperative treatment of spinal tuberculosis with Isoniazid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: preoperative treatment of spinal tuberculosis with Isoniazid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: preoperative treatment of spinal tuberculosis with Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: preoperative treatment of spinal tuberculosis with Rifampicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: preoperative treatment of spinal tuberculosis with Ethambutol
Study: NCT02135042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01900834

Intervention type: OTHER
Intervention: No treatment given
Description: The participants will not receive any treatment
Study: NCT00654316

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: intradermal injection of 0.1ml BCG over the deltoid muscle
Study: NCT01733095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
Study: NCT00044863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erbitux (Cetuximab)
Description: 400 mg/m2 initial dose, 250 mg/m2 weekly
Study: NCT03629392

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High met/cys diet
Description: Dietary intervention with high contents of methionine and cysteine
Study: NCT01938963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborations in Health (COACH)
Description: Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
Study: NCT02586233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1040b
Description: DS-1040b for IV infusion (0.6 mg to 9.6 mg) over 6-hour period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (placebo comparator) for IV infusion over 6-hour period
Study: NCT02673892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Oriented Discharge Summary
Description: The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
Study: NCT03695640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Addition of magnesium sulfate as an adjuvant to levobupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous femoral nerve block
Description: continuous nerve block with levobupivacaine for treatment postoperative pain

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous femoral nerve block
Description: continuous nerve block with levobupivacaine for treatment postoperative pain
Study: NCT02713763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg/day
Study: NCT02919124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echoclip
Description: An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
Study: NCT03007485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Pulmonary Rehabilitation
Description: Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
Study: NCT03773926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-feedback therapy
Description: The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
Study: NCT01471704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189 50 mg
Description: Study Day 0: Single 50 mg dose of INX-08189 in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 240 mg verapamil HCL ER
Description: Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg dose of INX-08189 and 240 mg verapamil HCL ER
Description: Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning